Navigation Links
Pharmaxis Closes Share Purchase Plan
Date:6/29/2009

SYDNEY, June 29 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced it had raised A$7.2 million from its Share Purchase Plan which closed on 24 June 2009. Shareholders of the company were given the opportunity to purchase up to $5,000 worth of shares each at the $2.35 price paid by institutional investors in the recent placement.

A total of 1,584 shareholders participated in the plan under which the company will issue approximately 3 million new shares and receive funds of approximately $7.2 million.

Dr Alan Robertson, Chief Executive Officer of Pharmaxis said, "We are very encouraged and appreciative of the level of support from our shareholders. The total proceeds of the placement and share purchase plan of $54 million puts us in a strong position from which to take our products to the global markets."

Shares will be issued today, 30 June 2009, and are expected to be listed on the Australian Securities Exchange on 2 July 2009. Holding statements will be posted on or about 1 July 2009.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson
     Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:

     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

     United States:
     Brandon Lewis
     Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
2. New Pharmaxis Board Appointment
3. Pharmaxis Investor Conference Call
4. Pharmaxis Appoints French Distributor for Aridol(TM)
5. Pharmaxis Builds Senior Management Team
6. Pharmaxis Investor Conference Call
7. Pharmaxis Aridol Approved for Sale in Switzerland
8. Pharmaxis Investor Conference Call
9. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
10. New Pharmaxis Board Appointment
11. Pharmaxis Aridol Authorised for Sale in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Intelligent Implant ... by the FDA via 510(k) for sale in the United States. These components ... posterior thoraco-lumbar fusions. With one-level sales beginning in October of 2015, the company ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell ... Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, ...
(Date:4/27/2016)... ... 2016 , ... The Pittcon Organizing Committee is pleased to announce that Charles ... member of Committee since 1987. Since then, he has served in a number of ... chairman for both the program and exposition committees. In his professional career, Dr. Gardner ...
(Date:4/27/2016)... ... April 27, 2016 , ... NDA ... joined the company as an Expert Consultant. Mr. Clark was formerly a ... managing the development of small molecule monographs based on analytical methods. NDA ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):